

# Jan & Tom Lewis Migraine Treatment Program



↑ Dr. Kerry Knievel and team of headache specialists at the Jan & Tom Lewis Migraine Treatment Program offer a variety of options for treating migraine.

**A**PPROXIMATELY 39 MILLION MEN, women, and children in the United States – one billion people worldwide – know the debilitating pain of migraine. Migraine is the second-leading cause of days of disability in this country.

The Jan & Tom Lewis Migraine Treatment Program at Barrow Neurological Institute is dedicated to the comprehensive care of patients suffering from migraine. Barrow accepts the challenge of treating patients deemed “untreatable” and prides itself on pushing the boundaries of medicine. With this in mind, the migraine program’s vision is to become the leading destination for the treatment of migraine in the Phoenix metropolitan area, the state of Arizona, and across the Southwest.

Barrow’s migraine experts have the tools and expertise to accurately diagnose and treat migraine to minimize their effects on daily life. The solutions may include medications, injections, physical therapy, lifestyle changes, yoga, or a combination of therapies. In addition, the program conducts groundbreaking, innovative research to find more effective therapies to prevent and treat migraine.



**85%**

of chronic migraine sufferers are women



**1.2 MILLION**

visits to the emergency department every year are for acute migraine attacks



**157 MILLION**

workdays are lost each year in the US due to migraine

## BY THE NUMBERS



### CLINICAL IMPACT

**100,878**

BNI Clinic Visits

**77,000+**

Patients Treated

**5,000+**

Brain & Spine Surgeries



### GLOBAL IMPACT

**47**

Visiting Scholars from  
Argentina, Austria, Brazil,  
China, Chile, Colombia,  
Germany, India, Italy, Ireland,  
Israel, Mexico, Pakistan,  
Philippines, Portugal,  
Romania, Russia, Spain,  
South Korea, Turkey,  
United Kingdom

## PROGRAM ACCOMPLISHMENTS

Barrow is home to the world's leading specialists in migraine and headache. Jennifer Robblee, MD, joined our powerhouse team in November 2019 increasing our capacity to bring relief to people with migraine. Year after year, the Program is experiencing growth at the rate of approximately 20%, so the addition of Dr. Robblee was perfectly timed. When the COVID-19 crisis began, the Jan & Tom Lewis Migraine Treatment Program urgently converted the majority of clinic appointments to telemedicine, keeping patients safer at home. While more routine appointments were converted to telemedicine, the Program maintained in-person appointments for migraine patients who needed procedures for headache prevention and treatment, keeping these patients out of the emergency room and urgent care during the pandemic.

The Program has two additional, critically important team members. One is Keith Martir, who is a grant fulfillment manager. Keith will ensure the Program meets the requirements of philanthropic gifts and grant funding. He has extensive experience in grant management, grant reporting, grant oversight, and process improvement. The second is the new manager for research, Brandy Harmon, who devotes a portion of her time to migraine clinical trials. She will allow the Program to put innovative protocols into practice more efficiently. She will also manage the rigorous approval and budgeting process.

Further establishing the Jan & Tom Lewis Migraine Treatment Program as a leader in the field, Kerry Knievel, DO, director of the Program, submitted a chapter for a medical board book called *Comprehensive Review of Headache Medicine*.

## RESEARCH ADVANCES

The Program is currently taking part in several studies to evaluate new treatments for migraine. We have two studies currently enrolling participants and five in the approval process. One current study will evaluate the efficacy, safety, and tolerability of oral Atogepant for the prevention of migraine in participants with episodic migraine and the other for chronic migraine.

Barrow had a strong presence at the Headache Cooperative of the Pacific Winter Conference in January 2020. Posters at this conference were presented by Barrow residents Alexandra Nicholson, MD, and Shane Root, MD, who is the current headache fellow. Dr. Knievel is a board member for this organization, served as a panelist at the conference, and will serve as the organization's president in 2021.



Karissa Secora, MPAS, Alexandra Nicholson, MD, Kerry Knievel, DO, Shane Root, MD

The Jan & Tom Lewis Migraine Treatment Program was visible in publications featuring the latest migraine and headache research. Dr. Robblee, Dr. Knievel, and Karissa Secora, MPAS, published an article about the difficulties of diagnosing Spontaneous Intracranial Hypotension (SIH) in the May issue of the *Practical Neurology Journal*.

## ON THE HORIZON

Most efforts on behalf of the Program in the next year revolve around hiring key positions. In order to meet the demand for services, the Program will recruit another headache neurologist and a physician assistant or nurse practitioner. Barrow will also identify and recruit a research scientist whose work emphasizes understanding the mechanisms driving migraine and other types of head pain. The scientist will collaborate closely with migraine providers to develop new, more effective migraine therapies and prevention strategies. Additionally, the team will recruit and train one headache fellow per year.

In an effort to further strengthen clinical trials, the Program will look for a research coordinator to recruit patients and raise awareness of clinical trials. This person will also consent, inform, and enroll patients, schedule follow-up visits, and document the process.

## BY THE NUMBERS



### RESEARCH

**1,377**

Active Research Studies

**959**

Patients Enrolled in Clinical Trials

**\$11.3 MILLION**

Federal Research Grant Support



### DONOR IMPACT

**\$2.4 MILLION**

Basic & Translational Research

**\$5.28 MILLION**

Strategic Initiatives

**\$1.63 MILLION**

Education and Fellowship Programs

**\$1.97 MILLION**

Community Outreach Programs

## Jan & Tom Lewis Migraine Treatment Program



### THANK YOU FOR YOUR SUPPORT

The COVID-19 pandemic brought challenges we have never before experienced. Thanks to your generous support of the Jan & Tom Lewis Migraine Treatment Program, we were able to meet those challenges during these unprecedented times. While we provide unsurpassed patient care, our team is working tirelessly to find the next, best treatment for migraine and other headache disorders. We would not be able to expand our program, conduct groundbreaking research, or educate the next generation of headache physicians without your support.

With Gratitude,  
Kerry Knievel, DO  
Director, Jan & Tom Lewis Migraine Treatment Program  
Barrow Neurological Institute

↑ Jan Lewis (center) joins headache specialists Jennifer Robblee, MD, Kerry Knievel, DO, director of the Jan & Tom Lewis Migraine Treatment Program, Karissa Secora, MPAS, PA-C, and Courtney Schusse, MD at Barrow Neurological Institute.

Barrow Neurological Foundation's mission is simple: to be the catalyst of our donors' passion for transformation by providing the resources for Barrow Neurological Institute to achieve its mission of saving human lives through innovative treatment, groundbreaking, curative research and educating the next generation of the world's leading neuro clinicians.



Barrow Neurological Foundation  
124 W. Thomas Rd., Ste. 250  
Phoenix, AZ 85013  
[www.SupportBarrow.org](http://www.SupportBarrow.org)

**Angela Braun**  
Manager, Philanthropy  
602.406.1035  
[Angela.Braun@DignityHealth.org](mailto:Angela.Braun@DignityHealth.org)